

OCTOBER 11-12, 2024

Efficacy and Safety of BLV Monotherapy for Chronic Hepatitis Delta: Posttreatment Results Through 24 Weeks After the End of Treatment From an Interim Analysis of a Randomised Phase 3 Study MYR301

Soo Aleman¹, Pietro Lampertico^{2,3}, Maurizia Brunetto^{4,5}, Pavel Bogomolov⁶, Vladimir Chulanov⁷, Tatyana Stepanova⁸, Amos Lichtman⁹, Renee-Claude Mercier⁹, Dmitry Manuilov⁹, Sarah Arterburn⁹, Anu Osinusi⁹, Florence Christian-Cox⁹, Markus Cornberg¹⁰, Stefan Zeuzem¹¹, Heiner Wedemeyer^{10,12}

¹Department of Infectious Diseases, Karolinska University Hospital/Karolinska Institutet, Stockholm, Sweden; ²Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; ³Department of Pathophysiology and Transplantation, CRC "A. M. and A. Migliavacca" Centre for Liver Disease, University of Milan, Milan, Italy; ⁴Hepatology Unit, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Pisa, Italy; ⁵Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; ⁶M.F. Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russian Federation; ⁷Sechenov University, Moscow, Russian Federation; ⁹Gilead Sciences, Inc., Foster City, CA, USA; ¹⁰Clinic for Gastroenterology, Hepatology, Infectious Diseases, and Endocrinology, Hannover Medical School, Hannover, Germany; ¹¹Department of Medicine, University Hospital, Goethe-University, Frankfurt, Germany; ¹²RESIST, DZIF, and D-Solve


Introduction and Objective

- Hepatitis delta virus (HDV) infection causes the most severe form of chronic hepatitis,^{1,2} with prevalence estimates of between 10 and 20 million people worldwide³
- Bulevirtide (BLV) 2 mg is a first-in-class entry inhibitor approved in Europe, the Russian Federation, and Australia for chronic hepatitis delta (CHD)^{4,5} and is recommended by the European Association for the Study of the Liver guidelines for the treatment of CHD in adult patients with compensated liver disease⁵
- BLV 2 and 10 mg monotherapy for CHD have been demonstrated to be effective and safe over 144 weeks of treatment⁶⁻⁸
- On-treatment improvements in virologic and biochemical responses and liver stiffness, as well as low occurrence of liver-related outcomes, are supportive of the clinical benefits of long-term BLV monotherapy⁸

Objective: To evaluate the long-term efficacy and safety of BLV 2 or 10 mg monotherapy at study week 168, representing up to 144 weeks of treatment and 24 weeks after the end of treatment (EOT)

BLV, bulevirtide; **CHD**, chronic hepatitis delta; **EOT**, end of treatment; **HDV**, hepatitis delta virus. **1**. Alfaiate D, et al. *J Hepatol*. 2020;73(3):533-9. **2**. Rizzetto M, et al. *J Hepatol*. 2021;74(5):1200-11. **3**. Stockdale AJ, et al. *J Hepatol*. 2020;73:523-32. **4**. Hepcludex. European Medicines Agency SmPC. Gilead Sciences, Inc.; 2023. **5**. European Association for the Study of the Liver. *J Hepatol*. 2023;79:433-60. **6**. Wedemeyer H, et al. *N Engl J Med*. 2023;389:22-32. **7**. Wedemeyer H, et al. *J Hepatol*. 2024;81(4):621-9. **8**. Lampertico P, et al. *J Hepatol*. 2024;80(suppl 1):S92.


MYR301 Study Design



- MYR301 is a multicentre, open-label, randomised, Phase 3 study (NCT03852719) conducted in 4 countries (Germany, Italy, the Russian Federation, and Sweden)
- Primary endpoint
 - Combined response at week 48: HDV RNA undetectable or decreased by ≥2 log₁₀ IU/mL from baseline (BL) and alanine aminotransferase (ALT) normalisation¹
- Safety and efficacy endpoints at week 144 (EOT) and follow-up at 24 weeks after EOT (FU24) are presented

ALT, alanine aminotransferase; BL, baseline; BLV, bulevirtide; CHD, chronic hepatitis delta; CTP, Child-Turcotte-Pugh; EOS, end of study; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); FU48, follow-up at 48 weeks after EOT (week 192); HDV, hepatitis delta virus; qd, once daily; sc, subcutaneous; ULN, upper limit of normal. 1. Food and Drug Administration. Chronic hepatitis D virus infection: developing drugs for treatment guidance for industry. Draft guidance. November 2019.

Patient Disposition



- By group, 92% of the BLV 2 mg, 88% of the 10 mg, and 96% of the delayed treatment (DT)/BLV 10 mg groups completed study treatment (EOT)
- After EOT, 80%, 84%, and 84% of these groups, respectively, completed FU24


^aPatients in this group received no treatment for 48 weeks. Beginning at W48, they received BLV 10 mg through study W144. ^bOne death due to plasma cell myeloma. BLV, bulevirtide; DT, delayed treatment; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); W, week; WC, withdrawal of consent (reasons for withdrawal of consent unknown).

BL Demographics and Disease Characteristics

	BLV 2 mg (n = 49)	BLV 10 mg (n = 50)	DT/BLV 10 mg (n = 51)ª
Age, years, mean (SD)	44 (9)	41 (9)	41 (8)
Male sex, n (%)	30 (61)	30 (60)	26 (51)
Race, ^b n (%)			
White	41 (84)	43 (86)	40 (78)
Asian	8 (16)	6 (12)	11 (22)
Cirrhosis present, n (%)	23 (47)	24 (48)	24 (47)
Liver stiffness, kPa, mean (SD)	14.0 (8.2)	14.8 (9.3)	15.3 (9.0)
ALT, U/L, mean (SD)	108 (63)	123 (81)	102 (62)
HDV RNA, log ₁₀ IU/mL, mean (SD)	5.10 (1.20)	4.96 (1.46)	5.08 (1.36)
Genotype HDV-1, ^c n (%)	49 (100)	48 (96)	51 (100)
HBsAg, log ₁₀ IU/mL, mean (SD)	3.67 (0.52)	3.61 (0.59)	3.68 (0.47)
HBV DNA, log ₁₀ IU/mL, mean (SD)	1.30 (1.29)	1.08 (1.26)	0.89 (0.99)
HBV genotype, n (%)			
А	2 (4)	2 (4)	2 (4)
D	47 (96)	44 (88)	44 (86)
Other ^d /missing	0	4 (8)	5 (10)
Previous IFN therapy, n (%)	26 (53)	29 (58)	29 (57)
Concomitant HBV NA treatment, ^e n (%)	32 (65)	27 (54)	32 (63)


^aAt BL, 51 patients were assigned to DT/BLV 10 mg, and their data are reported here. One patient subsequently withdrew from the DT/BLV 10 mg group before receiving BLV and is not included in subsequent reporting of efficacy and safety. ^bBLV 10 mg arm: Black, n = 1. ^cBLV 10 mg arm: HDV GT 5, n = 1; missing HDV GT, n = 1. ^dBLV 10 mg arm: HBV GT E, n = 1; DT/BLV 10 mg arm: unclassified HBV GT, n = 2. ^eAll patients who started NA therapy at or after BL, except 1, started at BL or within 2 days of BL. **ALT**, alanine aminotransferase; **BL**, baseline; **BLV**, bulevirtide; **DT**, delayed treatment; **GT**, genotype; **HBsAg**, hepatitis B surface antigen; **HBV**, hepatitis B virus; **HDV**, hepatitis delta virus; **IFN**, interferon; **NA**, nucleos(t)ide analogue.

Undetectable (TND) HDV RNA Through EOT and FU24



Missing values equal failure. DT/BLV 10 mg group initiated BLV at W48.


BLV, bulevirtide; DT, delayed treatment; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); HDV, hepatitis delta virus; TND, target not detected; W, week.



Combined response, ALT normalisation, and virologic response rates were similar between groups at EOT, and decreased from EOT to FU24

Patients with missing values were considered nonresponders; 95% CIs were calculated based on the Clopper-Pearson exact method. ^aVirologic response and ALT normalisation. ^bALT normalisation was defined at Russian sites as ≤31 U/L for females and ≤41 U/L for males and at all other sites as ≤34 U/L for females and ≤49 U/L for males. ^cUndetectable HDV RNA or ≥2 log₁₀ IU/mL decline from baseline.

Virologic Relapse by FU48 in Patients With Undetectable HDV RNA at EOT, **BLV 2 mg Group**




In the BLV 2 mg group, 7 of 14 patients who were HDV RNA undetectable at EOT were undetectable at both FU24 and FU48

8

Relapse was defined as detectable HDV RNA during follow-up after undetectable HDV RNA at EOT. BLV, bulevirtide; ET, early termination; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); FU48, follow-up at 48 weeks after EOT (week 192); HDV, hepatitis delta virus; LLOQ, lower limit of quantitation; TD, target detected; TND, target not detected

Virologic Relapse by FU48 in Patients With Undetectable HDV RNA at EOT, **BLV 10 mg Group**




In the BLV 10 mg group, 9 of 25 patients who were HDV RNA undetectable at EOT were HDV RNA undetectable at both FU24 and FU48

9

Relapse was defined as detectable HDV RNA during follow-up after undetectable HDV RNA at EOT. BLV, bulevirtide; ET, early termination; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); FU48, follow-up at 48 weeks after EOT (week 192); HDV, hepatitis delta virus; LLOQ, lower limit of quantitation; TD, target detected; TND, target not detected

Virologic Relapse by FU48 in Patients With Undetectable HDV RNA at EOT, DT/BLV 10 mg Group



- In the DT/BLV 10 mg group (after 96 weeks on BLV), 6 of 26 patients who were HDV RNA undetectable at EOT remained undetectable at both FU24 and FU48
- Overall, among all groups, most virologic relapses occurred during the first 24 weeks after EOT

Relapse was defined as detectable HDV RNA during follow-up after undetectable HDV RNA at EOT.

BLV, bulevirtide; DT, delayed treatment; ET, early termination; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); FU48, follow-up at 48 weeks after EOT (week 192); HDV, hepatitis delta virus; LLOQ, lower limit of quantitation; TD, target detected; TND, target not detected.

HBsAg Loss and Liver-Related Clinical Outcomes

Number of Patients, n/N		2 mg 49)		BLV 10 mg (n = 50)		DT/BLV 10 mg (n = 50)	
Time point	BL to EOT	FU24	BL to EOT FU24 W		W48 (DT) to EOT	FU24	
HBsAg lossª	0/49	1/49	0/50	0/50	1/50	1/50	
Liver-related clinical outcomes ^b	0/49	0/46	0/50	0/47	1/50	1/49	

- Hepatitis B surface antigen (HBsAg) loss was rare at EOT and during posttreatment follow-up
- Liver-related clinical outcomes were rare
 - On treatment: 1 case of mild ascites in the DT/BLV 10 mg group
 - Posttreatment through FU24: 1 case of mild ascites in the DT/BLV 10 mg group

^aHBsAg loss was defined as HBsAg positive at BL and HBsAg negative at the visit. ^bLiver-related clinical outcomes included but were not limited to development of cirrhosis; liver decompensation, including development or worsening of jaundice, coagulopathy, ascites, hepatic encephalopathy, bleeding from varices, and liver failure; hepatocellular carcinoma; liver transplant; and liver-related death. Missing values remained missing. Posttreatment events were those that started after the last BLV dose date.

DT, delayed treatment; BL, baseline; BLV, bulevirtide; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); HBsAg, hepatitis B surface antigen; W, week.

Overall Safety Summary

	BLV 2 mg		BLV 10 mg		DT/BLV 10 mg	
Patients, n (%)	EOT (n = 49)	EOT to FU24 (n = 46)	EOT (n = 50)	EOT to FU24 (n = 47)	W48 (DT) to EOT (n = 51)	EOT to FU24 (n = 49)
Any AE	48 (98)	25 (54)	48 (96)	26 (55)	46 (92)	25 (51)
Any grade 3 or 4 AE	12 (24)	5 (11)	10 (20)	5 (11)	5 (10)	9 (18)
Any AE leading to withdrawal of BLV	0	N/A	0	N/A	0	N/A
Any SAE	3 (6)	2 (4)	6 (12)	3 (6)	3 (6)	4 (8)
ALT >10 × ULN after EOT ^a	N/A	5/46 (11)	N/A	4/46 (9)	N/A	3/48 (6)
Cirrhosis at BL	N/A	4/5 (80)	N/A	3/4 (75)	N/A	2/3 (67)
HDV rebound ^b	N/A	3/5 (60)	N/A	4/4 (100)	N/A	2/3 (67)
Posttreatment total bilirubin increase ^c	N/A	2/5 (40)	N/A	1/3 (33)	N/A	1/2 (50)
Death	0	0	0	0	1 (2) ^d	0

^aIncludes 2 additional patients who met criteria for ALT >10 × ULN, based on laboratory data reported in the Gilead global safety database. ^bIncrease in HDV RNA ≥2 log₁₀ IU/mL from tLOQ (if HDV RNA was less than LLOQ at EOT) or an increase of ≥2 log₁₀ IU/mL from the EOT value. ^cThe 2 additional patients from the safety database were not included in analysis. Includes increases in the total bilirubin category per the Child-Turcotte-Pugh scoring system after EOT. ^dDue to plasma cell myeloma, considered not related to BLV. **AE**, adverse event; **ALT**, alanine aminotransferase; **BL**, baseline; **BLV**, bulevirtide; **DT**, delayed treatment; **EOT**, end of treatment; **FU24**, follow-up at 24 weeks after EOT (week 168); **HDV**, hepatitis delta virus; **LLOQ**, lower limit of quantitation; **N/A**, not applicable; **SAE**, serious adverse event; **ULN**, upper limit of normal; **W**, week.

Overall Safety Summary

- No AEs led to premature study drug discontinuation, and no treatment-related SAEs or treatmentrelated deaths were reported through EOT
- Most posttreatment ALT elevations >10 × ULN were observed at the follow-up visit at 12 weeks after EOT
 - Of the 12 patients with ALT elevations >10 × ULN, posttreatment SAEs were seen in 7 (all of which resolved during follow-up), 5 discontinued the study early, and BLV was restarted in at least 5

Conclusions

- A subset of patients treated with BLV monotherapy for 2 to 3 years maintained virologic and biochemical responses 24 weeks after stopping BLV
- Virologic relapse occurred in over half of those patients who were HDV RNA undetectable at EOT and occurred most often in the first 24 weeks after EOT
- The rate of liver-related clinical outcomes while on BLV and through 24 weeks after treatment was low
- ALT increases occurred in a subset of patients after treatment discontinuation. Most of these patients had cirrhosis at baseline, associated HDV rebound, and SAEs (which resolved during follow-up)

Acknowledgements

- We extend our thanks to the patients, their families, and all participating investigators
- These studies were funded by Gilead Sciences, Inc.
- All authors contributed to and approved the presentation; medical writing support was provided by Olivia Harwood, PhD, of Red Nucleus, and was funded by Gilead Sciences, Inc.
- Correspondence: Soo Aleman, soo.aleman@ki.se


Disclosures

SAleman received honoraria for lectures and educational events from AbbVie; Biogen; Gilead Sciences, Inc.; GSK;
Janssen; Merck Sharp & Dohme; MYR GmbH; Roche; and Spring Bank Pharmaceuticals. PL reports speaking and teaching fees from and participation in advisory committees or review panels for AbbVie; Aligos Therapeutics; Alnylam Pharmaceuticals; Antios Therapeutics; Arrowhead Pharmaceuticals; Bristol Myers Squibb; Eiger Biopharmaceuticals; Gilead Sciences, Inc.; GSK; Janssen; Merck Sharp & Dohme; MYR GmbH; Roche; and Spring Bank Pharmaceuticals. MB reports receiving teaching/speaking fees, grants, and consulting fees from AbbVie; Altimmune; Gilead Sciences, Inc.; GSK; and Janssen. PB has received grants and speaking fees from AbbVie; Bayer; Gilead Sciences, Inc.; Hepatera; Merck Sharp & Dohme; Novo Nordisk; and R-Pharm. VC reports being a consultant and giving sponsored lectures for AbbVie; AstraZeneca; Bristol Myers Squibb; Gilead Sciences, Inc.; GSK; Hepatera; Merck Sharp & Dohme; Roche; and R-Pharm. TS and SZ report nothing to disclose. AL, RCM, DM, SArterburn, AO, and FCC are employees of Gilead Sciences, Inc., and may own stock in Gilead Sciences, Inc. MC reports honoraria from AbbVie; Falk; Gilead Sciences, Inc.; GSK; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Roche; Spring Bank Pharmaceuticals; and Swedish Orphan Biovitrum. HW reports honoraria for speaking or consulting from AbbOti; AbbVie; Boehringer Ingelheim; Bristol Myers Squibb; Eiger Biopharmaceuticals; Gilead Sciences, Inc.; Novartis; Roche; and Roche Diagnostics.



Back-Up Slides

Mean HDV RNA Over Time



- Mean HDV RNA values decreased through EOT in all treatment groups but increased in the posttreatment period
- Follow-up HDV RNA values were lower than those observed at BL

Missing values were excluded from analysis.

BL, baseline; BLV, bulevirtide; DT, delayed treatment; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); FU48, follow-up at 48 weeks after EOT (week 192); HDV, hepatitis delta virus.

Posttreatment SAEs

	BLV 2 mg	BLV 10 mg	DT/BLV 10 mg
Patients, n (%)	EOT to FU24 (n = 46)	EOT to FU24 (n = 47)	EOT to FU24 (n = 49)
Any SAEs ^a	2 (4)	3 (6)	4 (8)
Hepatitis D	1 (2)	2 (4)	0
Hepatitis acute	1 (2)	0	0
Hepatitis function abnormal	0	0	1 (2)
Liver injury ^b	0	0	1 (2)
Transaminases increased	0	1 (2)	1 (2)
Chronic hepatitis B	0	0	1 (2)

- Of the 9 posttreatment SAEs, 8 were hepatic events associated with increases in ALT and HDV RNA
- The SAE of liver injury was attributed to tramadol/dexketoprofen

^aTerms are from MedDRA. ^bAttributed to tramadol/dexketoprofen.

AE, adverse event; ALT, alanine aminotransferase; BLV, bulevirtide; DT, delayed treatment; EOT, end of treatment; FU24, follow-up at 24 weeks after EOT (week 168); HDV, hepatitis delta virus; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event.

Posttreatment SAEs, Additional Details

SAE PT (Reported Term)	Treatment Arm	ALT Increase	ALT Peak FU Day (U/L)	Onset/Resolution FU Day	HDV RNA at EOT log₁₀ IU/mL	HDV RNA Peak EOT–FU24 log ₁₀ lU/mL	SAE Outcome	BLV Restarted	Comment
Hepatitis D (Acute hepatitis in HDV reactivation)	2 mg	10 × ULN	783 ^b (44)	44/98	4.0	5.85	Resolved	Y	ED FU4
Hepatitis acute (Acute hepatitis)	2 mg	10 × ULN	1040 ^ь (110)	108/150	<lloq td="" tnd<=""><td>6.08</td><td>Resolved</td><td>Y</td><td>ED (FU D135; unscheduled)</td></lloq>	6.08	Resolved	Y	ED (FU D135; unscheduled)
Transaminases increased (High transaminases)	10 mg	10 × ULNª	594 ^ь (141)	141/162	<lloq td="" tnd<=""><td>5.16</td><td>Resolved</td><td>Y</td><td>-</td></lloq>	5.16	Resolved	Y	-
Hepatitis D (Post treatment hepatitis D flare)	10 mg	10 × ULN	810 (90)	90/130	<lloq td="" tnd<=""><td>4.80</td><td>Resolved</td><td>N</td><td>-</td></lloq>	4.80	Resolved	N	-
Hepatitis D (Acute hepatitis in HDV reactivation)	10 mg	10 × ULN	1240 (85)	85/140	<lloq td="" td<=""><td>5.93</td><td>Resolved</td><td>Y</td><td>ED FU12</td></lloq>	5.93	Resolved	Y	ED FU12
Chronic hepatitis B ^c (Exacerbation of chronic hepatitis B with a delta agent)	DT/10 mg	10 × ULNª	3912 ^b (62)	58/90	<lloq td="" tnd<=""><td>3.68</td><td>Resolved</td><td>N (TDF)</td><td>-</td></lloq>	3.68	Resolved	N (TDF)	-
Liver injury ^c (Acute liver damage)	DT/10 mg	10 × ULN	1655 ^ь (76)	71/140	4.05	5.96	Resolved	Y	SAE attributed to tramadol/dexketoprofen
Transaminases increased (Increased aminotransferase)	DT/10 mg	5 × ULN	264 (163)	87/-	<lloq td="" td<=""><td>5.12</td><td>Not resolved</td><td>Y</td><td>Post FU48 (FU D619)— resolution of SAE with normalisation of ALT/AST</td></lloq>	5.12	Not resolved	Y	Post FU48 (FU D619)— resolution of SAE with normalisation of ALT/AST
Hepatic function abnormal ^c (Decreased liver function)	DT/10 mg	5 × ULN	351 (87)	163/-	<lloq td="" td<=""><td>6.91</td><td>Not resolved</td><td>YÞ</td><td>ED FU24 (ascites^d; nonserious)</td></lloq>	6.91	Not resolved	YÞ	ED FU24 (ascites ^d ; nonserious)

^aCriteria met in safety database; clinical database ALT maximum >5 × ULN. ^bFrom the safety database. ^cLiver-related hospitalisation. ^dLiver-related clinical event. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BLV, bulevirtide; D, day; DT, delayed treatment; ED, early discontinuation; EOT, end of treatment; FU, follow-up; FU4, follow-up at 4 weeks after EOT (week 148); FU12, follow-up at 12 weeks after EOT (week 156); FU24, follow-up at 24 weeks after EOT (week 168); FU48, follow-up at 48 weeks after EOT (week 192); HDV, hepatitis delta virus; LLOQ, lower limit of quantitation; PT, preferred term; SAE, serious adverse event; TD, target detected; TDF, tenofovir disoproxil fumarate; TND, target not detected; ULN, upper limit of normal.

On-Treatment AEs by PT Occurring in >20% of Patients in Any Group

	BLV 2 mg	BLV 10 mg	DT/BLV 10 mg
Patients, n (%)	BL to EOT (n = 49)	BL to EOT (n = 50)	W48 to EOT (n = 50)
Any AEs ^a	48 (98)	48 (96)	46 (92)
Vitamin D deficiency	22 (45)	19 (38)	14 (28)
Headache	10 (20)	12 (24)	7 (14)
Leukopenia	10 (20)	9 (18)	7 (14)
Thrombocytopenia	10 (20)	8 (16)	7 (14)

Posttreatment AEs by PT Occurring in >10% of Patients in Any Group

	BLV 2 mg	BLV 10 mg	DT/BLV 10 mg
Patients, n (%)	EOT to FU48 (n = 46)	EOT to FU48 (n = 47)	EOT to FU48 (n = 49)
Any AEs ^a	31 (67)	34 (72)	30 (61)
ALT increased	16 (35)	8 (17)	17 (35)
AST increased	15 (33)	8 (17)	14 (29)
GGT increased	6 (13)	3 (6)	1 (2)
Thrombocytopenia	5 (11)	5 (11)	6 (12)
Lymphopenia	2 (4)	4 (9)	7 (14)
Transaminases increased	2 (4)	7 (15)	3 (6)
Fatigue	0	5 (11)	3 (6)

^aTerms are from MedDRA.

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BLV, bulevirtide; DT, delayed treatment; EOT, end of treatment; FU48, follow-up at 48 weeks after EOT (week 192); GGT, gamma glutamyltransferase; MedDRA, Medical Dictionary for Regulatory Activities; PT, preferred term.